BBIO Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - BridgeBio Pharma Inc

Watchlist Manager

Watchlist

Price: 66.25 USD -1.57% Market Closed

Market Cap: $13B

	BridgeBio Pharma Inc NASDAQ:BBIO	US
	St Barbara Ltd ASX:SBM	AU

Profitability Summary

BridgeBio Pharma Inc's profitability score is 37/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

94%

Strong 3Y Average Gross Margin

93%

Gross Margin is Increasing

54% > 94%

Negative Operating Margin

-67%

Negative 3Y Average Operating Margin

-1.200%

Operating Margin is Increasing

-8.996% > -67%

Negative Net Margin

-97%

Negative 3Y Average Net Margin

-1.313%

Net Margin is Increasing

-10.088% > -97%

Negative Free Cash Flow Margin

-61%

Negative 3Y Average Free Cash Flow Margin

-1.080%

Free Cash Flow Margin is Increasing

-8.593% > -61%

Exceptional ROE

32%

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-254%

ROIC is Increasing

-403% > -124%

View All

Hide

Collapse

37 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.